Evidence map›Paper›PMID 33650644›Full record

Observational studyInternational journal of oncology2021

circUBAP2 regulates osteosarcoma progression via the miR‑204‑3p/HMGA2 axis.

Weiguo Ma, Ning Xue, Junhua Zhang, Dan Wang, Xiaobin Yao, Lin Lin, Qingxia Xu

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in International journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  5. Review
  6. Article
  7. Circular RNAs: typical biomarkers for bone-related diseases.Journal of Zhejiang University. Science. B · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Circular RNAs With Efficacy in PreclinicalCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Weiguo MaDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Ning XueDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Junhua ZhangDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Dan WangDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Xiaobin YaoDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Lin LinDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Qingxia XuDepartment of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
Henan Cancer Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA (circRNA/circ)‑ubiquitin associated protein 2 (UBAP2), a newly recognized circRNA, serves a functional role in several types of tumor, including ovarian cancer, colorectal cancer and osteosarcoma. However, the precise roles and molecular mechanism underlying circUBAP2 in osteosarcoma (OS) are not completely understood. In the present study, the expression levels of circUBAP2, microRNA (miR)‑204‑3p and (HMGA2) were evaluated via reverse transcription‑quantitative PCR in OS tissues and cells. OS cell proliferation, migration, invasion and apoptosis were assessed by performing Cell Counting Kit‑8, Transwell and flow cytometry assays, respectively. HMGA2 protein expression levels were determined via western blotting. Dual‑luciferase reporter assays were performed to verify the interaction between circUBAP2 and miR‑204‑3p, and between miR‑204‑3p and HMGA2. An RNA immunoprecipitation (RIP) assay was conducted to confirm the interaction between circUBAP2 and miR‑204‑3p. The results demonstrated that circUBAP2 expression was significantly upregulated in OS tissues and cell lines compared with paracancerous tissues and hFOB1.19 cells, respectively. In addition, high circUBAP2 expression levels in patients with OS were associated with a lower survival rate compared with lower expression levels in patients with OS. The functional assays revealed that circUBAP2 knockdown significantly inhibited OS cell proliferation, migration and invasion, but increased OS cell apoptosis compared with the small interfering RNA‑negative control (si‑NC) group. The dual‑luciferase reporter and RIP assay results confirmed that circUBAP2 bound to miR‑204‑3p. Moreover, miR‑204‑3p expression was significantly downregulated in OS tissues compared with paracancerous tissues, and miR‑204‑3p expression was negatively correlated with circUBAP2 expression in OS tissues. Collectively, the results demonstrated that miR‑204‑3p was associated with circUBAP2 knockdown‑mediated inhibition of OS cell malignant behavior. Moreover, miR‑204‑3p was also identified as one of the direct targets of HMGA2. Collectively, the results indicated that compared with the si‑NC group, circUBAP2 knockdown significantly inhibited OS cell malignant behavior by binding to miR‑204‑3p, which subsequently regulated HMGA2 expression. Therefore, the present study demonstrated that circUBAP2 expression was upregulated in OS, and circUBAP2 regulated OS cell malignant behavior via the miR‑204‑3p/HMGA2 axis.

Indexed as

AdolescentAdultApoptosisBone NeoplasmsCell Line, TumorChildDisease ProgressionFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHMGA2 ProteinHumansMaleMicroRNAsNeoplasm StagingOsteosarcomaHMGA2 ProteinHMGA2 protein, humanMicroRNAsMIRN204 microRNA, humanRNA, Circularcircular RNA‑ubiquitin associated protein 2high mobility group A2microRNA-204-3pmigrationosteosarcoma

Identifiers

PMID33650644
PMCPMC7864148
OpenAlexW3125417167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.